Haleon PLC Sponsored ADR $HLN Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lessened its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 8.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,186,416 shares of the company’s stock after selling 670,780 shares during the period. Envestnet Asset Management Inc.’s holdings in Haleon were worth $64,462,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. JTC Employer Solutions Trustee Ltd boosted its holdings in shares of Haleon by 120.7% in the third quarter. JTC Employer Solutions Trustee Ltd now owns 712,229 shares of the company’s stock valued at $6,392,000 after acquiring an additional 389,467 shares in the last quarter. Archford Capital Strategies LLC acquired a new stake in Haleon in the third quarter worth approximately $2,149,000. Arlington Partners LLC boosted its stake in Haleon by 128.0% during the 3rd quarter. Arlington Partners LLC now owns 508,886 shares of the company’s stock valued at $4,565,000 after purchasing an additional 285,692 shares in the last quarter. New York State Common Retirement Fund acquired a new position in shares of Haleon during the 2nd quarter valued at $3,964,000. Finally, Acadian Asset Management LLC increased its position in shares of Haleon by 3,031.5% during the 2nd quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock valued at $55,813,000 after purchasing an additional 5,212,711 shares during the period. 6.67% of the stock is owned by institutional investors.

Haleon Trading Up 1.1%

NYSE HLN opened at $10.98 on Monday. The firm’s 50 day moving average price is $10.03 and its two-hundred day moving average price is $9.66. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. Haleon PLC Sponsored ADR has a twelve month low of $8.71 and a twelve month high of $11.42. The stock has a market cap of $48.90 billion, a price-to-earnings ratio of 28.15 and a beta of 0.19.

Analysts Set New Price Targets

Several research analysts recently weighed in on HLN shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft downgraded shares of Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Finally, Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.